コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus.
2 the organization of this protein complex for Kaposi's sarcoma-associated herpesvirus.
3 nfected with either human cytomegalovirus or Kaposi's sarcoma-associated herpesvirus.
4 f the human pathogens Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.
5 he gammaherpesviruses Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.
6 ing TRIM43, that control the reactivation of Kaposi's sarcoma-associated herpesvirus.
7 ted with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus.
11 ich tumor cells are consistently infected by Kaposi's sarcoma-associated herpesvirus and usually grow
12 d from a newly established and characterized Kaposi's sarcoma-associated herpesvirus- and Epstein-Bar
13 view the evidence for Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus as causal lympho
14 ciated polyomavirus, Epstein-Barr virus, and Kaposi's sarcoma-associated herpesvirus, because GEMs ha
16 c mechanisms by which Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus cause B-cell lym
19 tors (e.g., herpes simplex virus nectin1 and Kaposi's sarcoma-associated herpesvirus EphA2), or assoc
20 ovirus (HCMV), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus, establish laten
23 a 50 years ago, only one other virus, namely Kaposi's sarcoma-associated herpesvirus/human herpesviru
24 ed for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesviru
25 omolog, the oncogenic human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus/human herpesviru
26 nflammatory activities observed in MCD-like "Kaposi's sarcoma-associated herpesvirus-induced cytokine
27 Microbe, Chang and Ganem (2013) report that Kaposi's sarcoma-associated herpesvirus infection of lym
29 coding-polyadenylated nuclear (PAN) RNA from Kaposi's sarcoma-associated herpesvirus is conferred by
31 IFI16 knockdown disrupted the latency of Kaposi's sarcoma associated herpesvirus (KSHV) and induc
33 ing an m(6)A-modified hairpin present in the Kaposi's sarcoma associated herpesvirus (KSHV) ORF50 RNA
34 Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an on
36 r maturation of RRV, the closest relative of Kaposi's sarcoma-associated herpesvirus (KSHV) (a human
38 ymphomas (PELs) are causally associated with Kaposi's sarcoma-associated herpesvirus (KSHV) and 86% o
39 protein (SCP) of human tumor herpesviruses--Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste
42 ame 50 (ORF50) DNA template in the genome of Kaposi's sarcoma-associated herpesvirus (KSHV) and has b
43 s KSHV-miR-K12-11 and MDV-miR-M4, encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) and Marek
48 ed with the closely related gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) and the m
50 lytic cycles of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are induc
53 al carcinogens, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are two o
56 of arachidonic acid pathways of the host in Kaposi's sarcoma-associated herpesvirus (KSHV) biology h
57 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) cause lif
58 ive stages of the KSHV life cycle.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) causes AI
61 Here, we addressed whether the oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) deregulat
63 ent SCFAs stimulate lytic gene expression of Kaposi's sarcoma-associated herpesvirus (KSHV) dose depe
71 encoded by open reading frame 36 (ORF36) of Kaposi's sarcoma-associated herpesvirus (KSHV) enhances
81 inity tagged and purified all 89 proteins of Kaposi's sarcoma-associated herpesvirus (KSHV) from huma
84 ous transcription across the entirety of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome an
86 e found that most transcripts encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome un
89 y focal assembly of RNA polymerase II around Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i
90 ected cells.IMPORTANCE B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) harbor mu
99 we present an innovative approach to culture Kaposi's sarcoma-associated herpesvirus (KSHV) infected
100 d levels of viral lytic gene expression when Kaposi's sarcoma-associated herpesvirus (KSHV) infected
103 was undertaken to determine whether de novo Kaposi's sarcoma-associated herpesvirus (KSHV) infection
104 an effective small-animal model to study the Kaposi's sarcoma-associated herpesvirus (KSHV) infection
107 lar RNA degradation enzyme Xrn1 during lytic Kaposi's sarcoma-associated herpesvirus (KSHV) infection
108 mined the expression of the DDR genes during Kaposi's sarcoma-associated herpesvirus (KSHV) infection
111 script C19ORF66 and showed that it restricts Kaposi's sarcoma-associated herpesvirus (KSHV) infection
112 L) is a lymphogenic disorder associated with Kaposi's sarcoma-associated herpesvirus (KSHV) infection
122 Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a high
131 inhibiting viral gene expression.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is a path
133 ting their premature accumulation.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is an onc
135 predominantly canonical in nature.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associ
137 g the intracellular redox balance.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associ
138 l that enhance antiviral defenses.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is causal
152 d transmission in the oral cavity.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca
175 on of the STAT3 signaling pathway.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the et
180 ects in KSHV late gene expression.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the et
182 lytic phases.IMPORTANCE The K15P protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is though
189 HV68) ORF73 (mLANA) has sequence homology to Kaposi's sarcoma-associated herpesvirus (KSHV) latency-a
191 on factors which play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) latent an
194 factors (HIFs) play an important role in the Kaposi's sarcoma-associated herpesvirus (KSHV) life cycl
195 e factors (HIFs) play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) life cycl
196 r, Ago2 and DCP1A, in PB formation, and that Kaposi's sarcoma-associated herpesvirus (KSHV) lytic inf
197 at the constitutive AMPK activity restricted Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep
198 veloping germinal center B cells, can induce Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep
200 tic targets to control KS lesions.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) manipulat
202 DSBs) in DNA, although detail concerning how Kaposi's sarcoma-associated herpesvirus (KSHV) modulates
203 egy of selectively isolating VLVs by using a Kaposi's sarcoma-associated herpesvirus (KSHV) mutant th
207 ere, we identify a viral trimeric complex of Kaposi's sarcoma-associated herpesvirus (KSHV) open read
214 report that PABPC1 forms a complex with the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 pro
217 ncy-associated nuclear antigen (LANA) of the Kaposi's sarcoma-associated herpesvirus (KSHV) performs
218 associated nuclear antigen (LANA) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) plays a m
222 nprecedented mechanism of viral replication: Kaposi's sarcoma-associated herpesvirus (KSHV) stably cl
223 recently showed that the interaction between Kaposi's sarcoma-associated herpesvirus (KSHV) tegument
224 ed to murine gammaherpesvirus 68 (MHV68) and Kaposi's sarcoma-associated herpesvirus (KSHV) that esta
225 e kinase A2 (EphA2) is an entry receptor for Kaposi's sarcoma-associated herpesvirus (KSHV) that is e
226 sociated substrate) as a platform to promote Kaposi's sarcoma-associated herpesvirus (KSHV) trafficki
230 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) utilize c
232 o-electron microscopy (cryo-EM) structure of Kaposi's sarcoma-associated herpesvirus (KSHV) virion, a
233 rophoretic response of B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) were inve
234 e expression occurs upon superinfection with Kaposi's sarcoma-associated herpesvirus (KSHV), a common
237 iral FLICE-like inhibitor protein (vFLIP) of Kaposi's sarcoma-associated herpesvirus (KSHV), against
239 ncy is an integral part of the life cycle of Kaposi's sarcoma-associated herpesvirus (KSHV), an etiol
240 V1) lineage consists of human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus (KSHV), and clos
241 DNA tumor viruses Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), and huma
242 osely related to human herpesvirus 8 (HHV-8)/Kaposi's Sarcoma-associated herpesvirus (KSHV), and it i
243 luding human Epstein-Barr virus (EBV), human Kaposi's sarcoma-associated herpesvirus (KSHV), and muri
244 iruses, including the human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), and the
245 lular reservoir in individuals infected with Kaposi's sarcoma-associated herpesvirus (KSHV), and the
246 the replication of the oncogenic herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), by targe
247 aherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), can caus
248 , an immediate-early and tegument protein of Kaposi's sarcoma-associated herpesvirus (KSHV), causes s
249 n adaptive immunity, many viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), have evo
250 othelial cells during de novo infection with Kaposi's sarcoma-associated herpesvirus (KSHV), in cells
251 aherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), is assoc
252 (RRV), a close homolog of the human pathogen Kaposi's sarcoma-associated herpesvirus (KSHV), is compr
254 by viral endoribonucleases, including SOX in Kaposi's sarcoma-associated herpesvirus (KSHV), muSOX in
255 egument proteins of herpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), play key
256 50 promoters of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), respecti
258 infection and KS.IMPORTANCE The ability for Kaposi's sarcoma-associated herpesvirus (KSHV), the caus
259 rld primates and are distinct but related to Kaposi's sarcoma-associated herpesvirus (KSHV), the etio
262 on lymphoma (PEL) cells infected with latent Kaposi's sarcoma-associated herpesvirus (KSHV), the prom
264 (RFHVMn), the pig-tailed macaque homolog of Kaposi's sarcoma-associated herpesvirus (KSHV), was dete
265 viral OX2 (vOX2) immunoregulator encoded by Kaposi's sarcoma-associated herpesvirus (KSHV), we have
266 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), which ar
268 predominantly infected by the latent form of Kaposi's sarcoma-associated herpesvirus (KSHV), with vir
272 factor in the development and progression of Kaposi's sarcoma-associated herpesvirus (KSHV)-induced p
273 EBV infection and expressed in many EBV and Kaposi's sarcoma-associated herpesvirus (KSHV)-infected
274 n by HIV-1 promotes the aggressive growth of Kaposi's sarcoma-associated herpesvirus (KSHV)-related m
276 shown that, unlike glucose-addicted cancers, Kaposi's sarcoma-associated herpesvirus (KSHV)-transform
277 ies.IMPORTANCE We have previously shown that Kaposi's sarcoma-associated herpesvirus (KSHV)-transform
292 to recognize late gene promoters.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV; human her
293 16) recognizes nuclear episomal herpesvirus (Kaposi's sarcoma-associated herpesvirus [KSHV], Epstein-
294 ose relative of the human oncogenic pathogen Kaposi's sarcoma-associated herpesvirus, ORF52 is a high
295 EL clinical samples, and three extracavitary Kaposi's sarcoma-associated herpesvirus-positive solid l
296 s, the cofactor activity (CFA), by using the Kaposi's sarcoma-associated herpesvirus RCA homolog Kapo
297 genomes, those of human cytomegalovirus and Kaposi's sarcoma-associated herpesvirus, revealing trans
298 t HIV, together with a transient increase in Kaposi's sarcoma-associated herpesvirus viral load at we
300 be infected with the human pathogens, EBV or Kaposi's sarcoma-associated herpesvirus, we have used a